PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes

PolTREG announces it has received a Notice of Allowance from the US Patent Office covering the manufacturing of T-regulatory cells (T-reg) to treat Type-1 Diabetes (T1D), and ways the therapy is administered. The decision paves “the way for rapid, unimpeded commercialization of PolTREG’s cell therapies,” CEO Prof. Piotr Trzonkowski was quoted as saying in today’s press … Continued

PolTREG at J.P. Morgan Healthcare Conference

We are excited to announce that PolTREG will be attending the Biotech Showcase during J.P. Morgan Healthcare Week 2024 in San Francisco, from January 8 to 11. Meet CEO Prof. Piotr Trzonkowski and Chief Business Officer Mariusz Jabłoński to discuss PolTREG’s cutting-edge technology in Treg cell therapies as a promising new form of personalized treatment … Continued

PolTREG at 16th Polish Transplantation Society Congress

Join our CEO Prof. Piotr Trzonkowski at the 16th Polish Transplantation Society Congress inGdansk. On 20 October at 7:45am (room E) Prof. Piotr Trzonkowski will be taking the stage to present acaptivating lecture: Opportunities for Treg cells implementation in transplantation. Mark your calendars, and stay tuned for more details on thispresentation